Medicare recipients can access GLP-1 medications like Wegovy and Zepbound for a $50 monthly co-pay starting July 1 through the Medicare GLP-1 Bridge pilot program. This temporary initiative aims to improve access to anti-obesity drugs for eligible seniors, bypassing current federal restrictions that prevent Medicare Part D from covering medications prescribed solely for weight loss.
Which GLP-1 drugs are included in the $50 program?
The Medicare GLP-1 Bridge program provides a flat $50 co-pay to pharmacies for a one-month supply of specific medications. According to the program’s official website, the covered list includes:
- Wegovy: Available as a weekly injection or a daily pill.
- Zepbound: Available as a weekly injection.
- Foundayo: Available as a daily pill.
This pilot program operates outside of the standard Medicare Part D structure. It is scheduled to run through December 31, 2027, while policymakers discuss potential long-term solutions for obesity management.
While nearly 40% of Americans over age 65 live with obesity, this pilot program could potentially impact up to 22 million people, depending on their specific health profiles and BMI.
How can Medicare recipients qualify for the lower co-pay?
Eligibility is not universal. To access the $50 rate, patients must meet four specific criteria. First, you must have Medicare Part D drug coverage. Second, you cannot already receive coverage for a GLP-1 drug through Medicare. Third, you must not have Type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease, as Medicare may already cover medications for those specific conditions.
BMI and health requirements
The program also uses Body Mass Index (BMI) and existing health conditions to determine eligibility. According to program guidelines, you must be at least 18 years old and meet one of the following benchmarks:
- A BMI of 35 or higher.
- A BMI of 30 or higher, plus a diagnosis of diastolic heart failure, high blood pressure, chronic kidney disease, prediabetes, a previous heart attack or stroke, or peripheral artery disease.
- A BMI of 27 or higher, plus a diagnosis of prediabetes, a previous heart attack or stroke, or peripheral artery disease.
If you believe you qualify, contact your doctor immediately. They must send a prescription to your pharmacy and complete a prior authorization request to trigger the $50 co-pay.
Why is this a temporary pilot instead of a permanent benefit?
Current federal law prevents Medicare Part D from covering prescriptions intended purely for weight loss. While Medicare covers GLP-1 drugs for Type 2 diabetes and certain cardiovascular issues, the “weight loss only” designation remains a legal barrier for permanent coverage.
The government is using this “short-term demonstration” to gather data on how such access affects both patient health and federal spending. Dr. Mehmet Oz, administrator for the Centers for Medicare & Medicaid Services, stated that these drugs can reduce risks for myocardial infarction, stroke, kidney disease, and chronic joint pain. Dr. Oz noted that managing these conditions can ultimately reduce costs within the Medicare program.
What does this mean for the future of Medicare and obesity treatment?
The success of this pilot could shift how the federal government approaches chronic disease management. By lowering the barrier to entry for medications like Wegovy and Zepbound, the program tests whether preventative weight management reduces the long-term burden of expensive complications like heart failure and kidney disease.
However, medical experts urge cautious optimism regarding the data. Dr. Harlan Krumholz, a cardiologist and professor at the Yale School of Medicine, told TODAY.com that more evidence is required for the elderly population. He noted that most clinical trials for these drugs have not heavily enrolled people over the age of 70 or 80.
“The older you are, the less evidence there is from any trial about you,” Krumholz said. He emphasized that because older adults are at greater risk for health problems at lower body weights, continued research is vital to ensure these medications are safe and effective for the oldest Medicare recipients.
Frequently Asked Questions
Can I use this program if I have Type 2 diabetes?
No. If you have Type 2 diabetes, Medicare may already cover GLP-1 drugs under different provisions. This specific $50 bridge program is for those not already receiving coverage for that condition.
When does the Medicare GLP-1 Bridge program end?
The current program is scheduled to end on December 31, 2027, unless long-term legislative changes are made.
How much will I pay at the pharmacy?
Eligible participants pay a flat $50 co-pay for a one-month supply of covered medications.
Stay informed on the latest healthcare policy changes. Share this article with someone who might benefit, or subscribe to our newsletter for regular updates on Medicare and prescription drug news.